Department of Ophthalmology, Military University Hospital of Tunis, Faculty of Medicine of Tunis, Tunis, Tunisia.
Reseach Unit of Autoimmune Disease UR17DN02, Military University Hospital of Tunis, Tunis, Tunisia.
Cornea. 2021 Jun 1;40(6):726-732. doi: 10.1097/ICO.0000000000002589.
To compare efficiency and tolerance between topical 0.5% cyclosporine A (CSA) and fluorometholone (FML) for subepithelial infiltrates (SEI) complicating epidemic keratoconjunctivitis.
We conducted a prospective double-blind randomized study involving 72 eyes with SEI. Thirty-eight eyes were treated with topical FML (FML group) and 34 eyes with CSA 0.5% eye drops (CSA group). Treatment was considered successful in case of SEI reduction and visual acuity improvement. Tolerance was evaluated by Schirmer test value, burning on eye drops instillation, and conjunctival injection.
Baseline characteristics of both groups were similar (P > 0.05). After 3 months of the regimen, resolution of SEI was 3 times more observed in the FML group than that in the CSA group (P = 0.026). After 6 months, resolution of SEI was observed in 70% of the FML group and in 47% of the CSA group (P = 0.068). The recurrence of SEI was almost twice higher in the FML group than that in the CSA group (16% vs. 9%). FML was better tolerated during the first 3 months: a higher Schirmer test value (P = 0.0003), less burning on instillation (P = 0.242), and less conjunctival injection (P = 0.003). For the rest of the follow-up period, the 2 groups were comparable in tolerance. No ocular hypertension was noted.
Epidemic keratoconjunctivitis can evolve favorably under both FML and CSA. The effect of FML is faster and CSA is more durable with fewer recurrences. Both are safe therapeutic options for long-term control of SEI.
比较 0.5%环孢素 A(CSA)和氟米龙(FML)治疗暴发性角膜结膜炎合并上皮下浸润(SEI)的疗效和耐受性。
我们进行了一项前瞻性、双盲、随机研究,纳入 72 只患有 SEI 的眼睛。其中 38 只眼睛用 FML 滴眼(FML 组),34 只眼睛用 0.5% CSA 滴眼(CSA 组)。SEI 减少和视力改善视为治疗成功。通过泪液分泌试验值、滴眼时烧灼感和结膜充血评估耐受性。
两组的基线特征相似(P>0.05)。治疗 3 个月后,FML 组 SEI 消退率是 CSA 组的 3 倍(P=0.026)。治疗 6 个月后,FML 组 SEI 消退率为 70%,CSA 组为 47%(P=0.068)。FML 组 SEI 复发率几乎是 CSA 组的 2 倍(16% vs. 9%)。在治疗的前 3 个月,FML 组的耐受性更好:泪液分泌试验值更高(P=0.0003),滴眼时烧灼感更轻(P=0.242),结膜充血更轻(P=0.003)。在随访的其余时间内,两组的耐受性相当。未观察到眼压升高。
暴发性角膜结膜炎在 FML 和 CSA 治疗下均可好转。FML 的作用更快,CSA 的作用更持久,复发率更低。两者均是 SEI 长期控制的安全治疗选择。